FDA Approves TAUKLARIFY Imaging Agent for Alzheimer's Tau Detection

The U.S. FDA has approved TAUKLARIFY (florquinitau F 18 injection), a new PET imaging agent. This agent is designed to identify tau neurofibrillary tangle pathology in adults being evaluated for Alzheimer's disease. This approval offers clinicians and researchers a crucial new tool for earlier disease detection and a better understanding of Alzheimer's progression across various stages of cognitive impairment.